Results 81 to 90 of about 44,068 (237)

Electron compensation‐gated nanomotor for immunomodulation and microenvironment remodeling in bacterial pneumonia therapy

open access: yesBMEMat, EarlyView.
A nanomotor featuring an “electronic lock” via electron compensation in an Au‐Ag alloy ensures therapeutic precision. Near‐infrared light acts as a key, unlocking on‐demand Ag+ release for synergistic bactericidal action and microenvironment remodeling to potently treat bacterial pneumonia. Abstract Bacterial pneumonia treatment is severely hampered by
Chenglong Xue   +4 more
wiley   +1 more source

Value of adhesion molecules for evaluating the efficiency of therapy for ulcerative colitis and Crohn's disease

open access: yesТерапевтический архив, 2014
AIM: To define the value of adhesion molecules (sVCAM-1 integrin, P-selectin, E-selectin, and L-selectin) for the prediction and evaluation of the efficiency of treatment in patients with ulcerative colitis (UC) and Crohn's disease/MATERIAL AND METHODS ...
A I Parfenov   +8 more
doaj  

PSGL-1, ADAM8, and selectins as potential biomarkers in the diagnostic process of systemic lupus erythematosus and systemic sclerosis: an observational study

open access: yesFrontiers in Immunology
BackgroundEarly diagnosis and treatment of Systemic lupus erythematosus (SLE) and Systemic sclerosis (SSc) present significant challenges for clinicians.
Esther San Antonio   +19 more
doaj   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović   +11 more
wiley   +1 more source

Circulating monocyte partitioning and its alteration in hematological chronic neoplasms

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Circulating monocyte partitioning refers to the relative quantification of the three main monocyte subsets in the peripheral blood, namely classical (cMo), intermediate (iMo), and non‐classical (ncMo) monocytes, as assessed by flow cytometry, a new nomenclature described 15 years ago.
Sihem Tarfi   +4 more
wiley   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia   +2 more
wiley   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo   +7 more
wiley   +1 more source

Photodynamic Biomimetic Nanoparticles Accelerate Tumor Vascular Normalization Initiation

open access: yesExploration, EarlyView.
Platelet‐mimetic IA@PM integrates apatinib‐driven vascular normalization with ICG‐mediated photodynamic therapy, creating a self‐amplifying vascular normalization therapy (VNT)–photodynamic therapy (PDT) cycle that accelerates the onset of the vascular normalization window and potentiates antitumor treatment.
Yufei Liu   +6 more
wiley   +1 more source

Targeting L-Selectin Lymphocytes to Deliver Immunosuppressive Drug in Lymph Nodes for Durable Multiple Sclerosis Treatment. [PDF]

open access: yesAdv Sci (Weinh), 2023
Zhao Y   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy